The advantages of adaptive clinical study designs, such as stopping a study early based on interim results or adjusting sample size, are appealing. A survey of bioequivalence studies with adaptive designs in abbreviated new drug applications (ANDAs) is presented, demonstrating the utility of these designs in generic drug development.
The possibilities of stopping a clinical study earlier based on interim study results or to adjust the sample size during the study conduct are attractive features of adaptive clinical study designs. Herein, we present a survey summary of bioequivalence (BE) studies with adaptive designs in abbreviated new drug applications (ANDAs), reflecting the current status of its utility in generic drug development.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据